• About
  • Policies
  • What is open access
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • Scholarly Publications
      • Institute of Materials Science and Nanotechnology (UNAM)
      • View Item
      •   BUIR Home
      • Scholarly Publications
      • Institute of Materials Science and Nanotechnology (UNAM)
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month

      Thumbnail
      View / Download
      1.2 Mb
      Author(s)
      Bastug, Aliye
      Bodur, Hurrem
      Urartu Ozgur Safak, Seker
      Filazi, Nazlican
      Aydos, Omer
      Ebru Sahin, Kehribar
      Hanifehnezhad, Ali Reza
      Kazancioglu, Sumeyye
      Recep Erdem, Ahan
      Volkan, Aslan
      Cakir, Banu
      Sertcelik, Ahmet
      Ozkul, Aykut
      Date
      2022-01-20
      Source Title
      Turk Biyokimya Dergisi
      Print ISSN
      0250-4685
      Electronic ISSN
      1303-829X
      Publisher
      Walter de Gruyter GmbH
      Volume
      47
      Issue
      1
      Pages
      9 - 18
      Language
      English
      Type
      Article
      Item Usage Stats
      7
      views
      3
      downloads
      Abstract
      Background: There is a knowledge gap about the characteristics of neutralizing antibody (NAb) response in patients who recovered COVID-19. In this study, it is aimed to elucidate the factors affecting the presence and titers of antibodies up to 30-days after onset. Material and methods: A total of 129 laboratory-confirmed COVID-19 patients were enrolled. Clinical data were obtained retrospectively. SARS-CoV-2 specific NAb, IgM, and IgG antibody responses were analyzed. Results: SARS-CoV-2 specific NAb, IgM and IgG, were detected at the time of hospital discharge in 60.5%, 30.2%, and 51.9% of the patients, respectively. The median time for obtaining serum samples for antibody tests after symptoms’ onset was 11 days. The median titer of neutralizing antibody (SN50) was significantly higher in severe patients (25 vs. 7.5, p=0.009). Of the 23 severe patients, 52.2% (n=12) had higher NAb titers (i.e., SN50≥1:25) when compared to that in non-severe patients (OR=2.89; 95%CI=1.15–7.28, p=0.021), yet, the potential effect of follow-up time on NAb status and titers could not be ruled out. Conclusions: The presence of antibody response is not the only determinative factor for recovery. The presence and higher titers of NAb were detected more in severe patients than their non-severe counterparts. Survival analysis suggested that this difference could at least be partially explained by the length of follow-up through antibody testing (at discharge) after symptoms’ onset.
      Keywords
      Antibody response
      COVID-19
      Humoral immunity
      IgM and IgG
      Neutralizing antibodies
      Permalink
      http://hdl.handle.net/11693/111684
      Published Version (Please cite this version)
      https://doi.org/10.1515/tjb-2021-0200
      Collections
      • Institute of Materials Science and Nanotechnology (UNAM) 2256
      Show full item record

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCoursesThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCourses

      My Account

      Login

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 2976
      © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy